OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil device, a localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company operates in one segment being the device development for new medical treatments. Geographically, it derives maximum revenue from Europe and the rest from Australia, the Middle East, and the United Kingdom.
Contact
7 Eden Park Drive
Level 5, Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
18
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,977.05 | 7.05 | 0.09% |
| DAX 40 | 25,887.05 | 152.63 | -0.59% |
| Dow JONES (US) | 52,018.64 | 323.92 | -0.62% |
| FTSE 100 | 10,731.36 | 9.29 | 0.09% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 25,559.15 | 625.58 | -2.39% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,607.91 | 112.48 | -1.46% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |